Seth S Martin1, Robert P Giugliano2,3, Sabina A Murphy2,3, Scott M Wasserman4, Evan A Stein5, Richard Ceška6, José López-Miranda7,8, Borislav Georgiev9, Alberto J Lorenzatti10, Matti J Tikkanen11, Peter S Sever12, Anthony C Keech13, Terje R Pedersen14, Marc S Sabatine2,3,15. 1. Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 3. Harvard Medical School, Boston, Massachusetts. 4. Amgen, Thousand Oaks, California. 5. Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio. 6. Center of Preventive Cardiology, 3rd Department Internal Medicine, University General Hospital and First Medical Faculty, Prague, Czech Republic. 7. Lipids and Atherosclerosis Unit, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofía University Hospital, University of Cordoba, Cordoba, Spain. 8. CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObN), Cordoba, Spain. 9. Department of Cardiology, National Heart Hospital, Sofia, Bulgaria. 10. Cardiology Department, Cordoba Hospital, Cordoba, Argentina. 11. Folkhälsan Research Center, University of Helsinki, Helsinki, Finland. 12. International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, England. 13. Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia. 14. Oslo University Hospital, Ullevål and Medical Faculty, University of Oslo, Oslo, Norway. 15. Deputy Editor.
Abstract
Importance: Recent studies have shown that Friedewald underestimates low-density lipoprotein cholesterol (LDL-C) at lower levels, which could result in undertreatment of high-risk patients. A novel method (Martin/Hopkins) using a patient-specific conversion factor provides more accurate LDL-C levels. However, this method has not been tested in proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor-treated patients. Objective: To investigate accuracy of 2 different methods for estimating LDL-C levels (Martin/Hopkins and Friedewald) compared with gold standard preparative ultracentrifugation (PUC) in patients with low LDL-C levels in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk (FOURIER) trial. Design, Setting, and Participants: The FOURIER trial was a randomized clinical trial of evolocumab vs placebo added to statin therapy in 27 564 patients with stable atherosclerotic cardiovascular disease. The patients' LDL-C levels were assessed at baseline, 4 weeks, 12 weeks, 24 weeks, and every 24 weeks thereafter, and measured directly by PUC when the level was less than 40 mg/dL per the Friedewald method (calculated as non-HDL-C level - triglycerides/5). In the Martin/Hopkins method, patient-specific ratios of triglycerides to very low-density lipoprotein cholesterol (VLDL-C) ratios were determined and used to estimate VLDL-C, which was subtracted from the non-HDL-C level to obtain the LDL-C level. Main Outcomes and Measures: Low-density lipoprotein cholesterol calculated by the Friedewald and Martin/Hopkins methods, with PUC as the reference method. Results: For this analysis, the mean (SD) age was 62.7 (9.0) years; 2885 of the 12 742 patients were women (22.6%). A total of 56 624 observations from 12 742 patients had Friedewald, Martin/Hopkins, and PUC LDL-C measurements. The median difference from PUC LDL-C levels for Martin/Hopkins LDL-C levels was -2 mg/dL (interquartile range [IQR], -4 to 1 mg/dL) and for Friedewald LDL-C levels was -4 mg/dL (IQR, -8 to -1 mg/dL; P < .001). Overall, 22.9% of Martin/Hopkins LDL-C values were more than 5 mg/dL different than PUC values, and 2.6% were more than 10 mg/dL different than PUC levels. These were significantly less than respective proportions with Friedewald estimation (40.1% and 13.3%; P < .001), mainly because of underestimation by the Friedewald method. The correlation with PUC LDL-C was significantly higher for Martin/Hopkins vs Friedewald (ρ, 0.918 [95% CI 0.916-0.919] vs ρ, 0.867 [0.865-0.869], P < .001). Conclusions and Relevance: In patients achieving low LDL-C with PCSK9 inhibition, the Martin/Hopkins method for LDL-C estimation more closely approximates gold standard PUC than Friedewald estimation does. The Martin/Hopkins method may prevent undertreatment because of LDL-C underestimation by the Friedewald method. Trial Registration: ClinicalTrials.gov Identifier: NCT01764633.
RCT Entities:
Importance: Recent studies have shown that Friedewald underestimates low-density lipoprotein cholesterol (LDL-C) at lower levels, which could result in undertreatment of high-risk patients. A novel method (Martin/Hopkins) using a patient-specific conversion factor provides more accurate LDL-C levels. However, this method has not been tested in proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor-treated patients. Objective: To investigate accuracy of 2 different methods for estimating LDL-C levels (Martin/Hopkins and Friedewald) compared with gold standard preparative ultracentrifugation (PUC) in patients with low LDL-C levels in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk (FOURIER) trial. Design, Setting, and Participants: The FOURIER trial was a randomized clinical trial of evolocumab vs placebo added to statin therapy in 27 564 patients with stable atherosclerotic cardiovascular disease. The patients' LDL-C levels were assessed at baseline, 4 weeks, 12 weeks, 24 weeks, and every 24 weeks thereafter, and measured directly by PUC when the level was less than 40 mg/dL per the Friedewald method (calculated as non-HDL-C level - triglycerides/5). In the Martin/Hopkins method, patient-specific ratios of triglycerides to very low-density lipoprotein cholesterol (VLDL-C) ratios were determined and used to estimate VLDL-C, which was subtracted from the non-HDL-C level to obtain the LDL-C level. Main Outcomes and Measures: Low-density lipoprotein cholesterol calculated by the Friedewald and Martin/Hopkins methods, with PUC as the reference method. Results: For this analysis, the mean (SD) age was 62.7 (9.0) years; 2885 of the 12 742 patients were women (22.6%). A total of 56 624 observations from 12 742 patients had Friedewald, Martin/Hopkins, and PUCLDL-C measurements. The median difference from PUCLDL-C levels for Martin/Hopkins LDL-C levels was -2 mg/dL (interquartile range [IQR], -4 to 1 mg/dL) and for Friedewald LDL-C levels was -4 mg/dL (IQR, -8 to -1 mg/dL; P < .001). Overall, 22.9% of Martin/Hopkins LDL-C values were more than 5 mg/dL different than PUC values, and 2.6% were more than 10 mg/dL different than PUC levels. These were significantly less than respective proportions with Friedewald estimation (40.1% and 13.3%; P < .001), mainly because of underestimation by the Friedewald method. The correlation with PUCLDL-C was significantly higher for Martin/Hopkins vs Friedewald (ρ, 0.918 [95% CI 0.916-0.919] vs ρ, 0.867 [0.865-0.869], P < .001). Conclusions and Relevance: In patients achieving low LDL-C with PCSK9 inhibition, the Martin/Hopkins method for LDL-C estimation more closely approximates gold standard PUC than Friedewald estimation does. The Martin/Hopkins method may prevent undertreatment because of LDL-C underestimation by the Friedewald method. Trial Registration: ClinicalTrials.gov Identifier: NCT01764633.
Authors: Alberico L Catapano; Ian Graham; Guy De Backer; Olov Wiklund; M John Chapman; Heinz Drexel; Arno W Hoes; Catriona S Jennings; Ulf Landmesser; Terje R Pedersen; Željko Reiner; Gabriele Riccardi; Marja-Riita Taskinen; Lale Tokgozoglu; W M Monique Verschuren; Charalambos Vlachopoulos; David A Wood; Jose Luis Zamorano; Marie-Therese Cooney Journal: Eur Heart J Date: 2016-08-27 Impact factor: 29.983
Authors: W Greg Miller; Gary L Myers; Ikunosuke Sakurabayashi; Lorin M Bachmann; Samuel P Caudill; Andrzej Dziekonski; Selvin Edwards; Mary M Kimberly; William J Korzun; Elizabeth T Leary; Katsuyuki Nakajima; Masakazu Nakamura; Göran Nilsson; Robert D Shamburek; George W Vetrovec; G Russell Warnick; Alan T Remaley Journal: Clin Chem Date: 2010-04-08 Impact factor: 8.327
Authors: Vasanth Sathiyakumar; Jihwan Park; Asieh Golozar; Mariana Lazo; Renato Quispe; Eliseo Guallar; Roger S Blumenthal; Steven R Jones; Seth S Martin Journal: Circulation Date: 2017-10-16 Impact factor: 29.690
Authors: Seth S Martin; Michael J Blaha; Mohamed B Elshazly; Eliot A Brinton; Peter P Toth; John W McEvoy; Parag H Joshi; Krishnaji R Kulkarni; Patrick D Mize; Peter O Kwiterovich; Andrew P Defilippis; Roger S Blumenthal; Steven R Jones Journal: J Am Coll Cardiol Date: 2013-03-21 Impact factor: 24.094
Authors: Robert P Giugliano; Terje R Pedersen; Jeong-Gun Park; Gaetano M De Ferrari; Zbigniew A Gaciong; Richard Ceska; Kalman Toth; Ioanna Gouni-Berthold; Jose Lopez-Miranda; François Schiele; François Mach; Brian R Ott; Estella Kanevsky; Armando Lira Pineda; Ransi Somaratne; Scott M Wasserman; Anthony C Keech; Peter S Sever; Marc S Sabatine Journal: Lancet Date: 2017-08-28 Impact factor: 79.321
Authors: Seth S Martin; Michael J Blaha; Mohamed B Elshazly; Peter P Toth; Peter O Kwiterovich; Roger S Blumenthal; Steven R Jones Journal: JAMA Date: 2013-11-20 Impact factor: 56.272
Authors: Diego Lucero; Anna Wolska; Zahra Aligabi; Sarah Turecamo; Alan T Remaley Journal: Endocrinol Metab Clin North Am Date: 2022-07-08 Impact factor: 4.748
Authors: Gerald F Watts; Samuel S Gidding; Pedro Mata; Jing Pang; David R Sullivan; Shizuya Yamashita; Frederick J Raal; Raul D Santos; Kausik K Ray Journal: Nat Rev Cardiol Date: 2020-01-23 Impact factor: 32.419
Authors: Edward E Schneider; Sudipa Sarkar; Joseph B Margolick; Seth S Martin; Wendy S Post; Todd T Brown Journal: AIDS Res Hum Retroviruses Date: 2020-01-06 Impact factor: 2.205
Authors: Maureen Sampson; Clarence Ling; Qian Sun; Roa Harb; Mohmed Ashmaig; Russell Warnick; Amar Sethi; James K Fleming; James D Otvos; Jeff W Meeusen; Sarah R Delaney; Allan S Jaffe; Robert Shamburek; Marcelo Amar; Alan T Remaley Journal: JAMA Cardiol Date: 2020-05-01 Impact factor: 14.676
Authors: Ty Sweeney; Renato Quispe; Thomas Das; Stephen P Juraschek; Seth S Martin; Erin D Michos Journal: Expert Rev Precis Med Drug Dev Date: 2021-05-26